Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc. LPTX

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.


Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

PR Newswire 7 days ago

Leap Therapeutics Reports Second Quarter 2022 Financial Results

PR Newswire 7 days ago

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

PR Newswire July 12, 2022

Leap Therapeutics to Host Virtual R&D Day on July 12, 2022

PR Newswire June 27, 2022

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

PR Newswire May 26, 2022

Leap Therapeutics Reports First Quarter 2022 Financial Results

PR Newswire May 13, 2022

Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

PR Newswire March 11, 2022

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

PR Newswire March 2, 2022

Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

PR Newswire January 31, 2022

Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

PR Newswire January 24, 2022

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

PR Newswire January 18, 2022

Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

PR Newswire January 5, 2022

Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2022

Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

PR Newswire November 15, 2021

Leap Therapeutics Reports Third Quarter 2021 Financial Results

PR Newswire November 12, 2021

Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire September 24, 2021

Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants

PR Newswire September 22, 2021

Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire September 21, 2021

Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

PR Newswire September 16, 2021

Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

PR Newswire September 13, 2021